Key result
Elevated XIST expression linked to ~116% higher odds of anti-phospholipid syndrome.
Why the study?
The molecular mechanisms underlying anti-phospholipid syndrome, which predisposes to thrombosis and miscarriage, are still being explored.
Case-Control (n=105)
No
The lncRNA XIST and miRNA155 regulate the Gab2/TAK1 axis in APS patients, influencing inflammatory mediators and potentially serving as noninvasive diagnostic biomarkers.
Anti-phospholipid syndrome (APS) is an autoimmune disease characterized by thrombosis and miscarriage events. Still, the molecular mechanisms underlying APS, which predisposes to a wide spectrum of complications, are being explored. Seventy patients with primary and secondary APS were recruited, in addition to 35 healthy subjects. Among APS groups, the gene expression levels of XIST, Gab2, and TAK1 were higher along with declined miRNA155 level compared with controls. Moreover, the sera levels of ICAM-1, VCAM-1, IL-1ꞵ, and TNF-α were highly elevated among APS groups either primary or secondary compared with controls. The lncRNA XIST was directly correlated with Gab2, TAK1, VCAM-1, ICAM-1, IL-1ꞵ, and TNF-α. The miRNA155 was inversely correlated with XIST, Gab2, and TAK1. Moreover, ROC curve analyses subscribed the predictive power of the lncRNA XIST and miRNA155, to differentiate between primary and secondary APS from control subjects. The lncRNA XIST and miRNA155 are the upstream regulators of the Gab2/TAK1 axis among APS patients via influencing the levels of VCAM-1, ICAM-1, IL1ꞵ, and TNF-α which propagates further inflammatory and immunological streams. Interestingly, the study addressed that XIST and miRNA155 may be responsible for the thrombotic and miscarriage events associated with APS and provides new noninvasive molecular biomarkers for diagnosing the disease and tracking its progression.
No takes yet. Share an insight, caveat, or question.
Abd‐Elmawla et al. (2023) conducted a case-control in Anti-phospholipid syndrome (APS) (n=105). Elevated XIST expression vs. Healthy controls was evaluated on Association with anti-phospholipid syndrome (OR 2.16, 95% CI 1.2-3.6, p=0.004). Elevated expression of the long non-coding RNA XIST was significantly associated with anti-phospholipid syndrome (OR 2.16) and demonstrated predictive power for differentiating APS from healthy controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: